Notably, dimethyloxalylglycine (DMOG), a prodrug precursor of N-oxalylglycine, which inhibits multiple 2-oxoglutarate (2OG)-dependent oxygenases22, including the PHDs, decreases survival of human THP-1 AML cells23; however, the therapeutic significance of selective pharmacological PHD inhibition with consequent HIF-α upregulation in many diseases and malignancies, including AML, remains unknown. The gene discussed is PDC; the disease is acute myeloid leukemia.